Noopept normalizes parameters of the incretin system in rats with experimental diabetes

Bull Exp Biol Med. 2014 Jul;157(3):344-9. doi: 10.1007/s10517-014-2562-5.


Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection. These data provided a basis for studying the effect of Noopept on major indexes of the incretin system. Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood. Noopept had a normalizing effect on these parameters. This influence of Noopept was not related to the inhibition of a major enzyme metabolizing incretins (dipeptidyl peptidase IV). A reference drug sitagliptin also increased the contents of incretins and insulin, which was associated with the inhibition of dipeptidyl peptidase IV. It is known that GLP-1 increases NGF expression in the insular system. Our results suggest that the increase in incretin activity contributes to the antiapoptotic effect of Noopept on pancreatic β cells. The mechanism for an increase in blood GLP-1 level after oral application of Noopept requires further investigations.

MeSH terms

  • Animals
  • Blood Glucose
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy*
  • Dipeptides / pharmacology*
  • Dipeptidyl Peptidase 4 / blood
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Drug Evaluation, Preclinical
  • Glucagon-Like Peptide 1 / blood
  • Hypoglycemic Agents / pharmacology*
  • Incretins / physiology*
  • Insulin / blood
  • Male
  • Pancreas / drug effects
  • Pancreas / pathology
  • Pyrazines / pharmacology
  • Rats, Wistar
  • Sitagliptin Phosphate
  • Triazoles / pharmacology


  • Blood Glucose
  • Dipeptides
  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents
  • Incretins
  • Insulin
  • Pyrazines
  • Triazoles
  • ethyl phenylacetyl-Pro-Gly
  • Glucagon-Like Peptide 1
  • Dipeptidyl Peptidase 4
  • Sitagliptin Phosphate